Lunchtime Industry Symposium

Our industry supporters are welcome to host sessions during the lunchtime breaks in the WAAVP 2021 programme. The sessions are available throughout the event ( one per day) and free to attend for all registered participants.

Monday 19th July

Symposium Title: 
Detection, Prevention, and Treatment:
Developing a Continuum of Care Program to Address Antiparasitic Needs of Cats


  • Key Components of Parasite Prevention for Cats
    Dr. Jessica Rodriguez ,Zoetis
  • Priorities for Treating Parasites in Cats
    Dr. Adriano Vatta, Louisiana State University, USA
  • Evolution of Parasite Detection & Its Importance in Cats
    Dr. Yoko Nagamori, Zoetis

Tuesday 20th July

Symposium Activities:

  1. NexGard Combo spot on for cats, a new antiparasitic drug to help controlling ecto and endoparasites of cats
  2. Odile Bain Memorial Prize Awards

1. Symposium Details:

The symposium will first come back on the importance of ecto and endo parasites in cats, sharing the results of epidemiological surveys conducted in Europe and in Asia. Then in a second part, the symposium will introduce NexGard Combo, a spot on formulation of esafoxolaner, eprinomectin and praziquantel.


  • NexGard Combo spot on for cats
    Frederic Beugnet, Boehringer Ingelheim Animal Health, FR
  • The ever complex parasitism of cats – 20 min
    Donato Traversa, Faculty of Veterinary Medicine,Teramo, IT
  • NexGard combo – 15 min
    Frederic Beugnet, Boehringer Ingelheim Animal Health, FR

Key Topics: Anti-parasitic drugs and drug development Parasites of companion animals

2. Odile Bain Memorial Prize Awards
Presentation of the OBMP – Announcement of 2020 OBMP prizes and 2021 OBMP prizes – 15 min
Domenico Otranto,
WAAVP President, Chair of OBMP committee, Faculty of Veterinary Medicine, Bari, IT

Frederic Beugnet,
Boehringer Ingelheim Animal Health, FR

Wednesday 21st July

Symposium Title:
A newly developed broad-spectrum parasiticide treatment for dogs in an ever-changing landscape

Symposium Details:
Elanco’s acquisition of Bayer Animal Health positions Elanco as the world’s second largest provider of anti-parasitics. Elanco remains committed to ongoing investment in parasitology (including scientific studies presented at this WAAVP) and is now introducing Credelio Plus®, a novel oral endectocide for dogs. Active ingredients milbemycin oxime and lotilaner target larval and/or adult stages of various canine nematodes, and major tick and flea species, respectively.

Studies demonstrated Credelio Plus as highly effective (≥ 96.8%) against larval T. canis (L4) and A. caninum (immature adult L5). Efficacy against adult intestinal nematodes was confirmed by a multi-centre field study in veterinary practices in three European countries, proving to be highly efficacious (≥ 97.2%) in reducing the faecal egg count in dogs naturally infected with T. canis, A. caninum and T. vulpis.

The 100% prevention of heartworm disease is important considering many resistant isolates of D. immitis have been described from regions where this large multi-site field study was conducted. This study provided safety data in a long-term clinical setting with no dogs having treatment-related adverse reactions nor significant laboratory parameter alterations. In vitro genetic testing of 11 European isolates was conducted and compared to US isolates.

The three-month tick and flea field study demonstrated safety and efficacy against natural infestations by important species of ticks or fleas feeding on dogs, including the least susceptible arthropod R. sanguineus, and confirmed that dogs suffering from flea allergic dermatitis (FAD) may greatly benefit by administration of Credelio Plus.


  • The new Elanco, following the acquisition of Bayer Animal Health
    Patrick Meeus, Elanco, CH
  • Internal parasite impacts of a newly approved endectocide
    Brad Hayes, Elanco, UK
  • Heartworm field study and genetic analysis of EU and US heartworm isolates
    Lisa Young, Elanco, USA
  • Ecto-parasite impacts of a newly approved endectocide
    Sophie Forster, Elanco, UK

Key Topics: Parasites of companion animals; Anti-parasitic drugs and drug development; Arthropods; Helminths; Epidemiology

Thursday 22nd July

Symposium Title:
The Covid-19 pandemic: impacting human–animal interaction, owner awareness and the necessity for frequent deworming

Symposium Details:

The COVID-19 pandemic had dramatic impacts on humans and pets lives, as well as human-animal interactions.  People around the globe were forced into social distancing, raising many challenges and socio-economic concerns. Altogether, with the inconclusive reports regarding pets as potential carriers of the virus, there was a growing concern that pet animals would be abandoned. However, the opposite occurred, and there was an increased global demand for pet ownership in its broader sense; pet adoptions, veterinary care and training consultation, along with web-based requests for animal health information. While the positive benefits of pet ownership to mental and physical health is well studied, little was known about the impact on the mental and physical health of dogs. Studies analysing large datasets clearly demonstrated that there is an association between impaired quality of life of owners and their dogs, as well as increased behavioural challenges. While  human-animal interaction and the impact on physical and mental health are better understood, there is a gap of knowledge regarding  the role intensified human-animal interaction plays from the perspective of infectious-zoonotic pathogens, such as gastrointestinal helminths, e.g. Toxocara canis and T. cati. Higher density of pets, due to increased demand, particularly in (sub)urban areas, may seed the environment with gastrointestinal helminth eggs. This bears a risk for both constant reinfection of cats and dogs and transmission to humans at the same time. Based on the previously published high prevalence data on Toxocara spp., low frequency of deworming across Europe and the significant increase in pet animals needs to be considered in terms of pet owner information on regular deworming.

It is the aim of this Vetoquinol corporate symposium to share information on studies on human-animal interactions and the impacts on pet health with the zoonotic challenges of gastrointestinal helminths.


  • Paul A. M. Overgaauw
    Institute for Risk Assessment Sciences, Veterinary Faculty, Utrecht University, The Netherlands
  • Liat Morgan
    Metabolite Medicine Division, BLAVATNIK Centre for Drug Discovery, Tel Aviv University, Israel
  • Norbert Mencke
    Vetoquinol S.A, France

WAAVP2021, organisation and its affiliated groups on inclusion of an Industry symposium, are not endorsing any topics, content or opinions stated during these symposia.